Multivariate analysis of physicochemical characteristics of lipid based nanoemulsifying cilostazol—Quality by design

Pund, Swati; Shete, Yogesh; Jagadale, Sujata

doi:10.1016/j.colsurfb.2013.11.019

Cited by 48 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surprisingly, the surfactant mixture (Smix) had a negative influence on the solubilizing capacity of the PCs. Our result is in contrast with those reported by Pund et al 30 who investigated a nanoemulsifying system for CZL, where the solubility of the drug in the formulation was mainly dependent on the Smix composed of Tween ® 80 and Transcutol ® while Campul MCM as an oil phase was not of significant effect on the solubilizing capacity. This might be an additional advantage for our system reducing the risk of drug precipitation after dilution which occurs if the drug is solubilized mainly by the Smix.…”

Section: Determination Of Loading Capacitycontrasting

confidence: 56%

“…21 Such an increase in the globule size could be attributed to the expansion of the interfacial film by the co-surfactant present. On the other hand, these results are in contrast to those reported by Pund et al 30 who reported a decrease in the globule size by increasing the amount of Transcutol ® in a system composed of Capmul ® MCM, Tween ® 80, and Transcutol ® HP. The conflicting results may be due to the different behavior of the oily phases employed on the interfacial tension and fluidity by penetrating as well as the bending stress at the globule interface.…”

Section: Optical Clarity and Globule Size Measurementcontrasting

confidence: 56%

“…Additionally, pure CZL powder was filled into HGCs and the dissolution was measured in buffer pH 7 containing 280 mg SG (equivalent amount to that in the SNEGs). Aliquots of 5 mL were withdrawn at 15,20,25,30,45, and 60 minutes, filtered through 0.22 µm membrane filters and replaced with fresh medium. The concentration of CZL was determined spectrophotometrically at 257 nm against the corresponding blank.…”

Section: In Vitro Drug Releasementioning

confidence: 99%

See 2 more Smart Citations

Optimization, ex vivo permeation, and stability study of lipid nanocarrier loaded gelatin capsules for treatment of intermittent claudication

Sallam¹,

Bosca²

2015

IJN

View full text Add to dashboard Cite

In this study, an optimized nanodispersible oral dosage form (containing a lactate ester) was developed for cilostazol (CZL). CZL is a phosphodiesterase inhibitor used for intermittent claudication. We aimed to improve the dissolution rate and absorption of CZL giving it a better chance of oral bioavailability, and to evaluate its stability on storage. Suitable compositions of nanoemulsion preconcentrate formulations were screened via solubility and compatibility tests. Response surface methodology and a desirability approach were applied to optimize preconcentrates containing minimum amount of surfactant mixture, maximum amount of lipid, and possessing the smallest globule size, with the highest emulsification and dissolution rates and minimum risk of drug precipitation. As part of the optimization process, the main effect, interaction effects and quadratic effects of amounts of lipid, and surfactant/co-surfactant ratio on % transmittance, globule size, emulsification time, drug precipitation, and drug release were investigated. The optimized formulation consisting of 28.9% butyl lactate, 28.9% Capryol ® , 27.82% Solubilisant Gamma ® 2429, and 14.18% Transcutol ® possessing a globule size of 60 nm was mixed with Aerosil ® 200. This gave uniform free flowing granules, which were characterized for surface and powder properties. The self-nanoemulsifying granules (SNEGs) filled into hard gelatin capsules showed two- and threefold increase in CZL released compared with conventional tablet and pure drug, respectively. The amount of drug permeated using non-everted sac technique from the SNEGs was twofold higher than that permeated from the tablet suspension. The shelf life was 526 days at 25°C. Our study illustrated that the developed SNEGs, with bioenhancing ingredients, held great potential as a superior alternative to traditional oral formulations of CZL.

show abstract

Section: Determination Of Loading Capacitycontrasting

confidence: 56%

Section: Optical Clarity and Globule Size Measurementcontrasting

confidence: 56%

Section: In Vitro Drug Releasementioning

confidence: 99%

See 1 more Smart Citation

Optimization, ex vivo permeation, and stability study of lipid nanocarrier loaded gelatin capsules for treatment of intermittent claudication

Sallam¹,

Bosca²

2015

IJN

View full text Add to dashboard Cite

show abstract

“…Experiments were carried out to determine the mathematical relationship between the factors influencing the performance and characteristics of the formulation 23 of the terms indicate synergistic effect, while a negative sign indicates an antagonistic effect of the factors. The significance of the model was estimated by applying analysis of variance (ANOVA) at the 5% significance level as listed in Table 11.…”

Section: Optimization Of Tablets Using Experimental Designmentioning

confidence: 99%

Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes

Desai

Prabhakar

2014

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

show abstract

“…(continued ) confidence (Pund et al, 2014). Since each delivery system has its own unique pharmaceutical and physiological characteristics; therefore, appropriate consideration of independent variables is very much required in the designing of final product.…”

Section: Metforminmentioning

confidence: 99%

Novel drug delivery system: an immense hope for diabetics

et al. 2014

View full text Add to dashboard Cite

Context: Existing medication systems for the treatment of diabetes mellitus (DM) are inconvenient and troublesome for effective and safe delivery of drugs to the specific site. Therefore, investigations are desired to deliver antidiabetics using novel delivery approaches followed by their commercialization. Objective: The present review aims to provide a compilation on the latest development in the field of novel drug delivery systems (NDDSs) for antidiabetics with special emphasis on particulate, vesicular and miscellaneous systems. Methods: Review of literature (restricted to English language only) was done using electronic databases like Pubmed Õ and Scirus, i.e. published during [2005][2006][2007][2008][2009][2010][2011][2012][2013]. The CIMS/MIMS India Medical Drug Information eBook was used regarding available marketed formulation of antidiabetic drugs. Keywords used were ''nanoparticle'', ''microparticle'', ''liposomes'', ''niosomes'', ''transdermal systems'', ''insulin'', ''antidiabetic drugs'' and ''novel drug delivery systems''. Single inclusion was made for one article. If in vivo study was not done then article was seldom included in the manuscript. Results: The curiosity to develop NDDSs of antidiabetic drugs with special attention to the nanoparticulate system followed by microparticulate and lipid-based system is found to emerge gradually to overcome the problems associated with the conventional dosage forms and to win the confidence of end users towards the higher acceptability. Conclusion: In the current scientific panorama when the area of novel drug delivery system has been recognized for its palpable benefits, unique potential of providing physical stability, sustained and site-specific drug delivery for a scheduled period of time can open new vistas for precise, safe and quality treatment of DM.

show abstract

Multivariate analysis of physicochemical characteristics of lipid based nanoemulsifying cilostazol—Quality by design

Cited by 48 publications

References 27 publications

Optimization, ex vivo permeation, and stability study of lipid nanocarrier loaded gelatin capsules for treatment of intermittent claudication

Optimization, ex vivo permeation, and stability study of lipid nanocarrier loaded gelatin capsules for treatment of intermittent claudication

Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes

Novel drug delivery system: an immense hope for diabetics

Contact Info

Product

Resources

About